Table 4.
Selected Primary and Secondary Outcomes (Complete Cohort).
| CHUM (Selective TATT) N = 64* |
CHUS (Ticagrelor-DAPT) N = 108 |
Unadjusted p-value | |
|---|---|---|---|
| Overall Population | |||
| NACE | 17 (27%) | 21 (19%) | 0.342 |
| MACCE | 13 (21%) | 21 (19%) | 0.844 |
| Major Bleeding | 4 (7%) | 0 (0%) | 0.019 |
| Irreversible Events | 9 (15%) | 7 (6%) | 0.104 |
| LVT | 0 (0%) | 1 (2%) | 1.000 |
| Treatment Failure** (NACE or LVT) | 17 (27%) | 22 (20%) | 0.354 |
*Five CHUM patients without in-hospital events did not have clinical follow-up within 4 ± 1month post-MI at either the CHUM or the identified referring center. **“Treatment Failure” was a post hoc outcome consisting of MACCE, Major Bleeding, or LVT.
NACE: Net adverse clinical events. MACCE: Major adverse cardiovascular and cerebrovascular events. LVT: Left ventricular thrombus. LVEF: Left ventricular ejection fraction.